Enzolve Technologies to commence production of novel newborn screening kits for international markets
Enzolve Technologies has received substantial investment from Enterprise Ireland under the National Development Plan (2007-2013) and private investors. This investment will enable it to commence production of "NeoScreenPak", a range of diagnostic kits for screening a variety of disorders that effect newborn infants...
Read full article on the web Biotechnology Ireland May 01, 2008 or in pdf format 
Website supported by
Language Selection
